Expert Opinion on Emerging Drugs
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 3.8 | Q2 | 67.7% | 0.908 | Q2 | 81.3% |
| 2024 | 2.7 | Q2 | 53.8% | 1.034 | Q1 | 85.1% |
| 2023 | 2.7 | Q2 | 54.1% | 0.881 | Q1 | 82.4% |
| 2022 | 3.4 | Q2 | 62.5% | 0.891 | Q1 | 83.5% |
| 2021 | 3.9 | Q2 | 66.2% | 0.972 | Q1 | 86.0% |
| 2020 | — | — | 0.975 | Q2 | 84.8% | |
| 2019 | — | — | 0.801 | Q2 | 80.4% | |
| 2018 | — | — | 0.977 | Q2 | 83.6% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1744-7623
ISSN
1472-8214
country
GBcoverage
2000-2025